Astellas Advances Alefacept To Phase II For Renal Transplant Rejection Prevention
This article was originally published in PharmAsia News
Taking a step to expand its immunosuppressant pipeline, Astellas is initiating Phase II clinical trials in North America and Europe for its biologic ASP0485 (alefacept) to prevent renal transplant rejection, the firm announced Sept. 12
You may also be interested in...
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.
Exec talks about emerging markets in Asia, and how Astellas’ culture differs from other Japanese pharmas.
Astellas will purchase Biogen Idec's psoriasis biologic Amevive (alefacept) for $60 mil. plus royalties